• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:

    公开号:BE1020455A3
    申请号:E2012/0858
    申请日:2012-12-20
    公开日:2013-10-01
    发明作者:Buyser Dirk De；Benoit Heens
    申请人:Veos Nv；
    IPC主号:
    专利说明:

    Composition enriched in GLYCOPROTEINE AS A FOOD AND / OR ANIMAL FEED ADDITIVE AND / OR AS A THERAPEUTIC AGENT
    FIELD OF THE INVENTION
    The present invention relates to glycoprotein-enriched compositions and their use in the treatment and / or prevention of diseases, in particular gastrointestinal diseases. The present invention further relates to the use of a glycoprotein-enriched composition as a food or feed additive and / or therapeutic agent.
    BACKGROUND
    One of the problems for young children and young animals such as piglets, calves, puppies, kittens, etc. is the occurrence of diarrhea, especially after weaning.
    For example, intestinal diseases of piglets after weaning are one of the most common causes of disease and death. Intestinal diseases in intensive livestock farming and livestock cause huge economic losses due to reduced growth performance. Reducing teat diarrhea is one of the most important challenges in the pig industry. In commercial practice, the use of different additives is recommended as a way to help the piglets in this phase. The integrity of the intestinal barrier is essential for the proper functioning of the epithelial cells and to prevent pathogenic bacteria from penetrating. Several studies have confirmed that the permeability of the intestines in diarrhea increases.
    The diarrhea of young animals and young children is mainly caused by pathogenic organisms. To cause diarrhea, pathogenic organisms (eg bacteria such as enterotoxigenic Escherichia coli (ETEC), viruses (eg parvovirus) or parasites (eg Giardia)) must attach to the intestinal receptors of the intestines. The use of blood plasma as a feed additive for the prevention of diarrhea caused by E. coli has been extensively described in the literature, as well as the effects of spray-dried animal plasma and immunoglobulins on the performance of early weaned piglets and calves. The effect of feed plasma is usually explained by the presence of immunoglobulins that act as antibody-antigen on pathogenic organisms. Immunoglobulins include typical units in the form of light and heavy chains connected by S-S bridges. These glycoproteins have a high molecular weight in non-reduced SDS-PAGE, but after reduction are split into low-molecular weight substances in a reduced SDS-PAGE. SDS-PAGE analysis under non-reduced and under reduced conditions can show a clear difference between the immunoglobulins and the glycoproteins consisting of intermolecular S-S-linked glycoprotein subunits.
    PCT application WO 03/030918 relates to a pharmaceutical product or food supplement containing a preparation of blood plasma as an active ingredient, wherein the preparation contains a larger amount of complement system and / or antibodies (immunoglobulins) than normal. The complement system (CS) is a group of glycoproteins that are able to interact under specific conditions that leads to an improved immune response. The CS comprises proteins involved in the activation of immune cells and thereby directly acts on the immune system. The compositions according to WO 03/030918 require the removal of fibrinogen to avoid disturbance when liquid products are prepared from the composition. As a result, additional preparation steps are required to remove fibrinogen. The compositions according to WO 03/030918 are also particularly heat sensitive, whereby any kind of heat treatment is excluded. This is not obvious when dietary supplements or pharmaceutical products are provided and sterility is required.
    Antimicrobial drugs are not only used for therapeutic use in animal feed. However, improper and excessive use of antibiotics has stimulated the growth of resistant organisms, causing disease control problems. There is therefore a need for agents that have a similar effect to antibiotics but do not entail the risk of resistance.
    SUMMARY OF THE INVENTION
    The present invention is based on the observation that glycoprotein-enriched compositions can advantageously be used to reduce the incidence and severity of bowel diseases.
    A first aspect of the invention relates to a glycoprotein-enriched composition comprising an at least 10% higher concentration of glycoproteins compared to the natural glycoprotein source, the enriched glycoprotein fraction consisting essentially of non-intermolecular SS-linked glycoprotein subunits, as measured by non-reduced and reduced SDS-PAGE. More specifically, the glycoprotein-enriched composition is prepared from human blood plasma, pig blood plasma, bovine blood plasma, horse blood plasma, sheep blood plasma or bird blood plasma.
    In a particular embodiment, the present invention relates to a glycoprotein-enriched composition according to the present invention, wherein the glycoprotein-enriched composition is prepared from eggs, whey, or other glycoprotein-containing natural sources. More specifically, the glycoprotein-enriched composition is further characterized in that it contains an at least 10% lower albumin concentration in comparison with the natural source of lycoprotein.
    In yet another particular embodiment, the glycoprotein-enriched composition of the present invention is prepared from non-immunized blood plasma.
    According to another embodiment, the present invention relates to a food or feed supplement in solid or liquid form, characterized in that the food or feed supplement comprises a glycoprotein-enriched composition according to the present invention. More specifically, the food or feed supplement further comprises an animal feed selected from the group consisting of one or more of corn, sorghum, meat, barley, wheat, soy, peanut, rapeseed oil, whey, dairy products, blood flour, bone meal, fish meal, fats and oils, amino acids, vitamins and minerals, to form a ration.
    According to yet another embodiment, the present invention relates to a glycoprotein-enriched composition or a food or feed supplement according to the present invention for use as a medicament, more particularly for use in the treatment and / or prevention of food-borne diseases of young mammals, more in particular for use in the treatment and / or prevention of gastrointestinal diseases, more in particular for use in the treatment and prevention of intestinal diseases and more particularly for use in the treatment and prevention of diarrhea , and more preferably teat diarrhea.
    According to yet another embodiment, the present invention relates to the use of a glycoprotein-enriched composition or a food or feed supplement according to the present invention as a food supplement.
    BRIEF DESCRIPTION OF THE FIGURES
    The present invention will be illustrated with reference to the following figures, which are intended solely as an illustration. The invention should not be limited in any way to this.
    Figure 1 represents an SDS-PAGE gel separation under reducing conditions.
    Figure 2 represents an SDS-PAGE gel separation under non-reducing conditions.
    Figure 3 represents an SDS-PAGE gel separation under reducing conditions, wherein the non-immunoglobulin glycoprotein fraction is increased.
    Figure 4 represents an SDS-PAGE gel separation under reducing conditions, wherein the non-immunoglobulin glycoprotein fraction is increased.
    Figure 5 is a graph illustrating the efficacy of the glycoprotein-enriched compositions of the present invention.
    DETAILED DESCRIPTION OF THE INVENTION
    The singular forms "one," "the," and "it," as used herein, include both singular and plural referents, unless the context clearly dictates otherwise.
    The terms "comprising", "includes" and "consisting of" as used herein are synonymous with "containing" and "contains", are inclusive or not clearly defined and do not include additional, unnamed members, elements or process steps from. Nevertheless, when the term "comprising" is used to refer to the presence of a number of elements or steps, it is intended to include embodiments that are characterized in that they consist solely of said elements and steps.
    The indication of numerical ranges by means of endpoints contains all numbers and fractions that fall within the respective ranges, as well as the stated endpoints.
    The term "about", as used herein when referring to a measurable value such as a parameter, an amount, a duration, and the like, is intended to include variations from and from said value, in particular variations of +/- 10. % or less, preferably +/- 5% or less, more preferably +/- 1% or less and even more preferably +/- 0.1% or less of and from said value, insofar as such variations are appropriate to perform in the described invention. It is to be understood that the value to which the provision "approximately" refers itself is also described specifically and preferably.
    All documents cited in the present description are hereby incorporated by reference in their entirety.
    Unless otherwise stated, all terms used in the description of the invention, including technical and scientific terms, have the meaning as generally understood by one skilled in the art to which this invention belongs. Definitions of terms may be included by way of further explanation to better understand the teachings of the present invention.
    The present invention is based on the observation that glycoprotein-enriched compositions can advantageously be used to reduce the incidence and severity of bowel diseases.
    Although the use of blood plasma as a feed additive for the prevention of diarrhea caused by E. coli has been extensively described in the literature, the precise mechanism and the active components of the blood plasma are difficult to establish. Although it is generally believed that the active ingredient in the blood plasma is the immunoglobulins, the inventors have now surprisingly found that glycoprotein-enriched compositions enriched in the non-immunoglobulin-glycoprotein fraction have surprisingly good results and significant positive effects on treatment and / or prevention. of intestinal diseases. The treatment of animals in vivo with the glycoprotein-enriched compositions of the present invention gave a positive effect on the fecal score in the subacute phase of diarrhea.
    While the conventional blood plasma compositions of the prior art were specifically aimed at providing an effect on the immune system, the glycoprotein-enriched compositions of the present invention interact directly with the pathogenic organisms and not with the immune system. More specifically, it has been found that the glycoprotein-enriched composition of the present invention is particularly useful and effective against the adhesion of pathogenic organisms to the intestines. These pathogenic organisms include but are not limited to bacteria such as E. coli, Salmonella, Clostridium, Campylobacter, Shigella etc., viruses such as norovirus, rotavirus, adenovirus, astrovirus, parvovirus, cytomegalovirus etc. and parasites such as Giardia, Entamoeba, Cryptosporidium etc. .
    Thus, a first aspect of the invention relates to a glycoprotein-enriched composition comprising at least a 10% higher concentration of glycoproteins compared to the natural glycoprotein source, the enriched glycoprotein fraction consisting essentially of non-intermolecular SS-linked glycoprotein subunits, as measured by means of non-reduced and reduced SDS-PAGE. More preferably, the glycoprotein-enriched compositions comprise at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90% or at least 100% higher concentration of glycoproteins than the natural glycoprotein source, the enriched glycoprotein fraction consisting essentially of non-intermolecular SS-linked glycoprotein subunits, thereby the immunoglobulin fraction of the glycoproteins is excluded. Accordingly, the glycoprotein-enriched composition of the present invention provides an enriched non-immunoglobulin-glycoprotein fraction compared to the non-immunoglobulin-glycoprotein fraction of the natural glycoprotein source.
    While the term "glycoprotein enriched composition" generally refers to the composition as a whole, the enriched composition obtained from, for example, a blood plasma product, the term "enriched glycoprotein fraction" specifically refers to a fraction of the glycoprotein enriched composition that specifically enriched. In the compositions of the present invention, in particular, the glycoprotein fraction that does not contain immunoglobulins is enriched.
    The non-immunoglobulin glycoprotein fraction or the glycoprotein fraction consisting essentially of non-intermolecular SS-linked glycoprotein subunits can be measured using conventional biochemical techniques such as, for example, performing separation of the protein fraction based on electrophoretic mobility on an SDS-PAGE . A comparison of the separation on an SDS-PAGE gel under non-reduced and reduced conditions provides a measurement of the glycoprotein fraction consisting of non-intermolecular SS-linked glycoprotein subunits, since the SDS-PAGE gel separation under reducing conditions (e.g. by briefly boiling the protein fraction or performing the separation in the presence of a reducing agent such as dithiothreitol (DTT) or 2-mercaptoethanol (beta-mercaptoethariol / BME)) provides proteins that are denatured by reduction of the disulfide bonds.
    Figure 1 shows an example of such SDS-PAGE gel separation (marker in lane 4) under reducing conditions, comparing pig plasma (lanes 1A and 1B) with the composition enriched in non-immunoglobulin glycoprotein (lanes 2A and 2B) and the composition depleted of non-immunoglobulin glycoprotein (lanes 3A and 3B). Figure 2 shows the same compositions in an SDS-PAGE gel separation under non-reducing conditions, showing the clear difference between the total glycoprotein fraction (under non-reduced conditions) and the non-immunoglobulin glycoprotein (under reduced conditions).
    In a particular embodiment of the present invention, the glycoprotein-enriched composition is prepared from human blood plasma, pig blood plasma, bovine blood plasma, horse blood plasma, sheep blood plasma, bird blood plasma or any other conventional blood plasma source.
    In particular embodiments, the glycoprotein-enriched composition makes up at least 30% of the blood plasma product. More specifically, the glycoprotein-enriched composition makes up at least 35%, 40%, 45% or 50% of the blood plasma product.
    In yet another particular embodiment of the present invention, the glycoprotein-enriched composition is prepared from eggs, whey, or other glycoprotein-containing natural sources.
    In a particular embodiment of the present invention, the glycoprotein-enriched composition is further characterized in that it comprises an at least 10% lower albumin concentration compared to the natural glycoprotein source.
    In yet another particular embodiment of the present invention, the glycoprotein-enriched composition further comprises an immunoglobulin fraction, wherein the immunoglobulin fraction is preferably at least partially or completely inactivated by conventional inactivation techniques such as heat inactivation, enzymatic inactivation or any other type of conventional inactivation technique such as, for example, but not exclusively radiation or other chemical treatments.
    In a particular embodiment of the present invention, the glycoprotein-enriched composition is prepared from non-immunized blood plasma. Since the enriched fraction of the glycoprotein enriched composition preferably does not contain immunoglobulin glycoproteins, it is not required that the animals from which blood plasma is used be immunized prior to obtaining the blood plasma. Thus, a method is provided that is completely natural and does not include immunization steps.
    When used in animals or humans, the glycoprotein-enriched composition of the invention can be easily administered by mixing directly into animal feed, or using it separately from the animal feed as a supplement in an edible carrier that is subsequently mixed with the animal feed.
    Therefore, the present invention further relates to food supplements in solid or liquid form, characterized in that the food supplement comprises a glycoprotein-enriched composition according to the present invention. The inventors have also noted that the glycoprotein-enriched composition of the present invention can be prepared for administration separately from the animal feed by mixing it with non-toxic, acceptable, edible carriers to make immediate-release or slow-release formulations, such as in the technique is known. Such edible carriers may be solid or liquid, such as, for example, corn starch, lactose, sucrose, soy flakes, peanut oil, olive oil, sesame oil and propylene glycol (and used as a supplement or over the feed). The dosage forms may also contain adjuvants, such as preservatives, stabilizers, wetting agents or emulsifiers, solution-promoting agents, etc. They may also contain other therapeutically valuable substances.
    In a particular embodiment, the nutritional supplement according to the present invention further comprises an animal feed selected from the group consisting of one or more of corn, sorghum, meat, barley, wheat, soy, flour, peanut, rapeseed oil, whey, milk products, blood meal, bone meal , fish meal, fats and oils, amino acids, vitamins and minerals, to form a ration.
    The glycoprotein-enriched composition and nutritional supplements of the present invention are preferably administered by mouth, preferably to young animals (such as, but not limited to, piglets, calves, puppies, kittens, etc.) and children.
    The present invention further provides the use of the glycoprotein-enriched composition of the present invention as an animal feed and food additive. The term "food" as used herein includes food for human consumption. The term "animal feed" as used herein includes food for animal consumption. The term "food or feed additive, as used herein, refers to an ingredient, additive, component, or supplement suitable for incorporation into human food or feed.
    Therefore, another aspect of the invention relates to the use of the glycoprotein-enriched composition of the present invention as a food or feed additive and food or feed additives comprising the glycoprotein-enriched composition of the invention. In particular, the glycoprotein-enriched composition is provided as a food or feed additive for individuals susceptible to gastrointestinal disease, such as post-weaning individuals. The glycoprotein-enriched composition may be useful, for example, as a food or feed additive for weaned piglets.
    The active agent content of a feed that is fed to animals as a supplement to the feed may be 2-20 times the value provided for feed. The active agent of a premix must be increased according to its mixing ratio with the feed or the food. The active ingredient content of a premix can be, for example, 10-100 times the values provided for animal feed. More preferably, a premix may be 10, 20, 30, 40, 50, 60, 70, 80, 90 or 100 times the values provided for animal feed.
    Examples of suitable animal feed materials according to the invention include, but are not limited to, bran, such as wheat bran, rice bran, barley bran, and millet bran; food processing by-products such as tofure residue, starch pulp, copramel, sake cake, soy sauce cake, beer broth, distillation residue from sweet potatoes, and fruit or vegetable juice pulp; grains such as corn, rice, wheat, barley, and oats; oilseed flour such as soybean flour, rapeseed flour, cottonseed flour, linseed flour, sesame seed flour and sunflower flour; animal feed of animal origin, such as fish meal, casein, skimmed milk powder, whey powder, meat and bone meal, feather meal and blood meal; leaf flour such as alfalfa flour; and such.
    Veterinary compositions are provided within the scope of the present invention which comprise as an active ingredient the glycoprotein-enriched composition or food or feed supplements of the present invention.
    The term "veterinary composition" includes the full range of compositions for internal administration and animal feeds and beverages that can be consumed by animals. Typical veterinary dosage forms for internal administration are oral dosage forms such as pastes, solutions, tablets, etc. However, injectable compositions are also provided. The compositions of the present invention can also be drug-containing animal feeds, foods, premixes, drinking waters and drinking water additives. For mixing in animal feed, the composition is usually provided as a powder and for mixing in drinking water, the composition is provided as a liquid.
    The present invention further relates to the glycoprotein-enriched composition or food or feed supplements of the present invention for use as a medicament and more particularly for use in the treatment and / or prevention of food-borne diseases of young mammals. The present invention further relates to the use of the glycoprotein-enriched composition or food or feed supplements of the present invention in the preparation of a medicament.
    In particular, the present invention relates to the glycoprotein-enriched composition or food or feed supplements according to the present invention for use in the treatment and / or prevention of gastrointestinal disease and more particularly for use in the treatment and / or prevention of bowel disease, preferably for use in the treatment and / or prevention of diarrhea, and more preferably teat diarrhea. The present invention further relates to the use of the glycoprotein-enriched composition or food or feed supplements according to the present invention in the preparation of a medicament for the treatment and / or prevention of gastrointestinal disease and more particularly the treatment and / or or prevention of bowel disease, preferably the treatment and / or prevention of diarrhea, and more preferably teat diarrhea.
    The present invention therefore also relates to methods for the treatment and / or prevention of gastrointestinal diseases or food-borne diseases of young mammals by administration of the glycoprotein-enriched composition or food or feed supplements according to the present invention.
    The term "gastrointestinal disease", as used herein, refers to a disease of the digestive system, such as diseases of the esophagus, stomach, the first, second and third parts of the duodenum, fasting gut, convolute, the ileo-caecal complex , the large intestine, the sigmoid and the rectum. Gastrointestinal diseases, in particular gastrointestinal diseases characterized by diarrhea, may be associated with a number of pathogens. The pathogens can be, but are not limited to, bacteria, viruses, stress factors, nutrition, etc. The most important bacteria that cause gastrointestinal diseases are Escherichia coli (E. coli) and members of the genera Clostridium, Lawsonia and Brachyspira. The most important viruses that cause gastrointestinal diseases are rotaviruses, coronaviruses and transmissible gastroenteritis virus. In addition to infection with bacteria and viruses, gastrointestinal diseases can be caused by numerous changes, such as stress, which may be associated with irregular feed intake, feed structure, hygiene and housing of the animal, and insufficient space for the crib in the cage. The gastrointestinal disease can also be caused by (early) weaning. Thus it has been observed that a number of changes take place in the early weaned body, such as morphological and functional changes of the small intestine, changes in colonization of the intestines with predominantly E. coli and weakening of the immune system. Non-infectious stress factors involved in the development of gastrointestinal diseases of, for example, piglets include but are not limited to the age of the piglets when weaned from their mother animal and the sudden switchover of sow's milk that supplies the piglets with immunoglobulins, to animal feed.
    Therefore, in particular embodiments of the invention, the gastrointestinal disease is a bowel disease. The term "bowel disease," as used herein, refers to a disease related to or associated with the abdominal walls or intestines. The gastrointestinal or intestinal disease can be characterized by diarrhea. The term "diarrhea" as used herein refers to a condition where there is three or more times loose or fluid bowel movements or stools per day.
    The term "weaning", as used herein, refers to switching an infant to what his adult diet will be and putting the breast milk supply or its substitute in a bottle. The infant is considered "weaned" when he does not receive breast milk or a substitute for it in a bottle. In particular embodiments, the glycoprotein-enriched composition or food or feed supplements of the present invention are provided for use in the treatment and prevention of gastrointestinal diseases in weaned animals, more particularly weaned farm animals, such as weaned piglets. 3-
    The inventors have experimentally determined that the glycoprotein-enriched composition or nutritional or nutritional supplements of the present invention have a positive effect on the treatment of gastrointestinal disease. In particular, the inventors have determined experimentally that the glycoprotein-enriched composition or food or feed supplements of the present invention have a positive effect on the treatment of diarrhea.
    Accordingly, the glycoprotein-enriched composition or food or feed supplements of the present invention are provided as being useful for the treatment or prevention of gastrointestinal disease, more particularly an intestinal disease and most particularly a gastrointestinal disease and / or intestinal disease which is characterized by diarrhea in an individual who needs it. The glycoprotein-enriched composition or nutritional or nutritional supplements of the present invention are further provided for use in the treatment and prevention of diarrhea.
    The present invention is seen as useful for all mammals, including humans. The term "individual" as used herein, therefore, typically refers to animals, more particularly mammals such as humans and other primates, including non-human primates such as chimpanzees and other species of apes and monkeys; farm animals such as cattle, sheep, pigs, goats and horses; pets such as dogs and cats; laboratory animals, including rodents such as mice, rats, guinea pigs and the like. In particular embodiments, the individual is an agricultural animal such as a cow, sheep, pig, goat, or horse. In other particular embodiments, the invention is particularly useful for the treatment and prevention of gastrointestinal disease in cattle, sheep and pigs. Most particularly, the invention is provided as being useful in non-ruminating farm animals. In particular embodiments, the individual is a pig.
    The concentration of the glycoprotein-enriched composition or food or feed supplements according to the present invention in a veterinary composition according to the invention depends on various factors such as the goal to be achieved (prevention or treatment), the severity of the disease already established and the type of the composition concerned.
    In particular embodiments, the invention provides veterinary compositions comprising the glycoprotein-enriched composition or food or feed supplements of the present invention and an excipient such as a pharmaceutically acceptable carrier. The pharmaceutically acceptable carrier can be selected from known excipients such as, but not limited to, water, carboxymethyl cellulose, propylene glycol, polyethylene glycol, and oil such as, for example, corn oil for solutions, or sodium carbonate, whey powder for powder formulations.
    In particular embodiments, the compositions of the present invention comprise the glycoprotein-enriched composition or food or feed supplements of the present invention as the major or sole active ingredient.
    The present invention also relates to the use of the glycoprotein-enriched composition or food or feed supplements of the present invention as a food supplement.
    The present invention also relates to a method for the preparation of a glycoprotein-enriched composition or a food or feed supplement according to the present invention, comprising the following steps: (a) providing a blood plasma composition or a natural, glycoprotein-containing composition; and (b) enriching the blood plasma composition or the natural, glycoprotein-containing composition such that the concentration of glycoproteins in the glycoprotein-enriched composition is 10% higher compared to the blood plasma composition or the natural, glycoprotein-containing composition.
    The enrichment of the blood plasma composition or the natural glycoprotein-containing composition can be carried out according to various methods, including general and non-general methods, such as, but not limited to, different types of precipitation methods, adsorption methods, chromatographic methods and / or filtration separation methods.
    The present invention will now be illustrated with reference to the following non-limiting examples.
    EXAMPLES
    Example 1: Preparation of glycoprotein-enriched compositions
    The glycoprotein-enriched compositions according to particular embodiments of the present invention were prepared by chromatographic techniques. Figure 3A shows in lane number 2 the enriched composition wherein the non-immunoglobulin glycoprotein fraction was increased by 15% compared to the non-enriched plasma fraction in lane 1. Figure 3B shows two different colorings of the glycoprotein enriched composition according to the present invention (lane 2 from figure 3A). On the one hand, a staining was performed with Coomassie blue (Figure 3B - S1) which stains all proteins and, on the other hand, a staining was performed with a Glyco-Staining (Figure 3B - S2) which stains specific glycoproteins. This indicates the glycoproteins in the glycoprotein-enriched composition of the present invention.
    Figure 4 shows in lane numbers 2A and 2B the enriched composition wherein the non-immunoglobulin glycoprotein fraction was increased by 26% and 30% respectively compared to the non-enriched plasma fraction in lane 1.
    Calculations of the degree of enrichment were made using conventional calculations and BioSciTec software.
    Example 2: Effects of the glycoprotein-enriched compositions
    The glycoprotein-enriched compositions of the present invention were fed in an in vivo model to early weaned pigs, the piglets being challenged with enterotoxicogenic Escherichia coli. Figure 5 shows the results of these tests. Early weaned pigs fed the glycoprotein-enriched composition showed no mortality and a significant decrease in teat diarrhea.
    权利要求:
    Claims (14)
    [1]
    A glycoprotein-enriched composition comprising an at least 10% higher concentration of glycoproteins compared to the natural glycoprotein source, the enriched glycoprotein fraction consisting essentially of non-intermolecular SS-linked glycoprotein subunits, as measured by non-reduced and reduced SDS-PAGE .
    [2]
    The glycoprotein-enriched composition according to claim 1, wherein the glycoprotein-enriched composition is prepared from human blood plasma, pig blood plasma, bovine blood plasma, horse blood plasma, sheep blood plasma or bird blood plasma.
    [3]
    The glycoprotein-enriched composition according to claim 1, wherein the glycoprotein-enriched composition is prepared from eggs, whey, or other glycoprotein-containing natural sources.
    [4]
    The glycoprotein-enriched composition according to any of claims 1 to 3, wherein the glycoprotein-enriched composition is further characterized in that it contains an at least 10% lower albumin concentration compared to the natural glycoprotein source.
    [5]
    The glycoprotein-enriched composition according to any of claims 1 to 4, wherein the glycoprotein-enriched composition is prepared from non-immunized blood plasma.
    [6]
    Food or animal feed supplement in solid or liquid form, characterized in that the food or animal feed supplement comprises a glycoprotein-enriched composition according to any of claims 1 to 5.
    [7]
    The food or feed supplement according to claim 6, further comprising an animal feed selected from the group consisting of one or more of corn, sorghum, meat, barley, wheat, soy, peanut, rapeseed oil, whey, dairy products, blood meal, bone meal, fish meal , fats and oils, amino acids, vitamins and minerals, to form a ration.
    [8]
    A glycoprotein-enriched composition according to any one of claims 1 to 5 or a food or feed supplement according to claim 6 or 7 for use as a medicament.
    [9]
    A glycoprotein-enriched composition according to any one of claims 1 to 5 or a food or feed supplement according to claim 6 or 7 for use in the treatment and / or prevention of food-borne diseases of young mammals.
    [10]
    A glycoprotein-enriched composition according to any one of claims 1 to 5 or a food or feed supplement according to claim 6 or 7 for use in the treatment and / or prevention of gastrointestinal disease.
    [11]
    A glycoprotein-enriched composition according to any one of claims 1 to 5 or a food or feed supplement according to claim 6 or 7 for use in the treatment and / or prevention of bowel disease.
    [12]
    A glycoprotein-enriched composition according to any one of claims 1 to 5 or a food or feed supplement according to claim 6 or 7 for use in the treatment and / or prevention of diarrhea, more preferably teat diarrhea.
    [13]
    Use of the glycoprotein-enriched composition according to any of claims 1 to 5 or a food or feed supplement according to claim 6 or 7 as a food supplement.
    [14]
    A method for the preparation of a glycoprotein-enriched composition according to any of claims 1 to 5 or a food or feed supplement according to claim 6 or 7, comprising the steps of: (a) providing a blood plasma composition or a natural, glycoprotein-containing composition; and (b) enriching the blood plasma composition or the natural, glycoprotein-containing composition such that the concentration of glycoproteins in the glycoprotein-enriched composition is 10% higher in comparison with the blood plasma composition or the natural, glycoprotein-containing composition.
    类似技术:
    公开号 | 公开日 | 专利标题
    RU2485800C1|2013-06-27|System for domestic animals feeding
    JP5933906B2|2016-06-15|Methods and compositions for preventing or treating inflammatory diseases
    JP5112865B2|2013-01-09|Composition for preventing or treating hemoglobinuria or myoglobinuria
    JP6822734B2|2021-01-27|Oral rehydration composition and its method
    US20040116527A1|2004-06-17|Agents against stress-induced diseases
    Johnson-Delaney2014|Ferret nutrition
    JP6538043B2|2019-07-03|Methods and compositions for improving renal function
    RU2712942C2|2020-02-03|Compositions and methods, including medium chain triglycerides, for treating epilepsy
    BE1020455A3|2013-10-01|Composition enriched in GLYCOPROTEINE AS A FOOD AND / OR ANIMAL FEED ADDITIVE AND / OR AS A THERAPEUTIC AGENT.
    ES2798772T3|2020-12-14|Composition for muscle building and method of building muscle
    JP5409989B2|2014-02-05|Food and drink for animals containing sesamin
    JP2007238581A|2007-09-20|Composition for ameliorating arthritis
    JP2004141130A|2004-05-20|Dog food for exclusive use for specific dog species
    US9474292B1|2016-10-25|Nutritional powder including brewer's yeast, aronia extract, and cranberry extract for animals
    WO2014025019A1|2014-02-13|Animal feed and stress reducer for industrial animals
    JP6161494B2|2017-07-12|Oral composition for improving muscle atrophy and a muscle atrophy improving agent containing plasma protein
    JP2011063552A|2011-03-31|Physical activity promoter
    WO2011037092A1|2011-03-31|Livestock feed composition and method for feeding livestock with same
    JP2018519322A|2018-07-19|Marine peptides and muscle health
    JP6602416B2|2019-11-06|Methods and compositions for improving renal function
    Hernández2020|Effect of Feed Additives and Toxic Elements on Swine Growth Performance, Nutrient Digestibility, Immune Function and Reproductive Performance
    WO2017057610A1|2017-04-06|Oral composition
    US20200068921A1|2020-03-05|Food Compositions and Methods for Preventing Copper-Associated Hepatopathies
    JP2005278442A|2005-10-13|Method for increasing vitamin e in cow milk
    NL2007581C2|2013-04-15|Method for preventing osteochondrosis.
    同族专利:
    公开号 | 公开日
    EP2606741A1|2013-06-26|
    EP2606741B1|2014-04-16|
    KR20140114830A|2014-09-29|
    ES2470335T3|2014-06-23|
    CA2860123A1|2013-06-27|
    PL2606741T3|2014-08-29|
    US20150018535A1|2015-01-15|
    DK2606741T3|2014-06-23|
    CN104144612A|2014-11-12|
    BR112014015193A8|2017-06-13|
    BR112014015193A2|2017-06-13|
    WO2013092861A1|2013-06-27|
    IN2014MN01459A|2015-04-17|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    US4096244A|1975-06-20|1978-06-20|Canada Packers Limited|Immunoglobulins for administration to piglets|
    US5372811A|1993-12-03|1994-12-13|American Meat Protein Corporation|Animal feed supplement containing co-spray dried plasma protein and amylase|
    WO2000056166A1|1999-03-23|2000-09-28|American Protein Corporation|Animal plasma supplement for aquaculture|
    US20030190314A1|2001-01-30|2003-10-09|The Lauridsen Group|Methods and compositions of treatment for modulating the immune system of animals|
    WO2003030918A1|2001-10-08|2003-04-17|Nutricia N.V.|Pharmaceutical product or food supplement and intermediate product to be used therewith|
    CN1923028A|2006-09-30|2007-03-07|王焕玉|Concentrated feed for pig and its preparing process|
    US7138262B1|2000-08-18|2006-11-21|Shire Human Genetic Therapies, Inc.|High mannose proteins and methods of making high mannose proteins|
    MXPA03006818A|2001-01-30|2004-10-15|Lauridsen Group Inc|Methods and compositions for modulating the immune system of animals.|
    CN1772287A|2005-11-02|2006-05-17|白求恩医科大学制药厂|Application of hedgehog fungus mycelium glucoprotein in preparing medicine|PL226770B1|2014-10-29|2017-09-29|Michałowski Paweł Andrzej|Preparation stimulating improvement of health and weight gain of young mammals, preferably young pigs, improving the fattening result and method for feeding this preparation|
    法律状态:
    优先权:
    申请号 | 申请日 | 专利标题
    EP11195701|2011-12-23|
    EP11195701.5A|EP2606741B1|2011-12-23|2011-12-23|Glycoprotein enriched composition as a food and feed additive and/or as a therapeutic agent|
    US201161581202P| true| 2011-12-29|2011-12-29|
    US201161581202|2011-12-29|
    [返回顶部]